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DIETARY AND LIFESTYLE MODIFICATIONS IN THE PREVENTION OF 
EPITHELIAL OVARIAN CANCER RECURRENCE 
ALEXANDRA M. TORRES 
ABSTRACT 
Background  
Advanced stage epithelial ovarian cancer (EOC) presents with an extremely poor 
prognosis. While some patients respond well to standard treatments of chemotherapy and 
cytoreductive surgery, the recurrence rate is high and five-year survival is low. The 
importance of nutritional eating and a healthy lifestyle has been recognized as a 
protective factor against the development of many cancers. There may be a role for 
dietary and lifestyle interventions on reducing the recurrence of EOC, thereby prolonging 
survival.  
Literature Review Findings 
A review of the literature was performed, focusing on dietary and lifestyle patterns and 
their effects on the development and recurrence of epithelial ovarian cancers. In general, 
carotenoids, flavonoids, cruciferous vegetables, and flaxseed rich diets have all been 
proposed to reduce the risk of developing ovarian cancer. Conversely, red and processed 
meats, and foods with high glycemic index have been associated with an increased risk of 
ovarian cancer development. Additionally, obesity and high Body Mass Index (BMI) 
have been linked to increased cancer risk as well as increased mortality rates from cancer.  
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Proposed Methods  
Given the broad spectrum of dietary and lifestyle recommendations for prevention of 
EOC, many providers are not aware of what information they can give to their patients 
regarding this topic. A Continuing Medical Education (CME) lecture summarizing the 
most up-to-date literature on the topic of lifestyle interventions to increase EOC survival 
would be beneficial. A one hour long course will be offered for CME credit to expand the 
knowledge base of providers and equip them with the resources necessary to educate 
patients on healthy lifestyle modifications in order to minimize ovarian cancer 
recurrence.  
Conclusions 
With a lack of definitive cure and poor overall prognosis for women diagnosed with 
advanced stage epithelial ovarian cancer, there is a need for alternative treatment options 
when traditional methods fail. There is promising evidence that a diet high in carotenoids, 
cruciferous vegetables, flaxseed, and several other nutritional components is beneficial in 
preventing development of ovarian cancer. A diet containing processed foods, red meats, 
dairy, and high sugar content has been associated with increased ovarian cancer risk.  It is 
possible that these dietary recommendations may apply to prevention of recurrence of 
EOC as well. The CME lecture will present the most up-to-date knowledge in the area of 
lifestyle interventions for the prevention of EOC. A curriculum for primary care and 
oncology health care providers will provide them with the tools necessary to provide their 
patients with nutrition and lifestyle recommendations that may prevent cancer recurrence.   
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INTRODUCTION 
Background 
Ovarian cancer is the most deadly gynecologic cancer in women1  This statistic is 
attributed in part to late stage at diagnosis due to a lack of specific symptoms and 
effective screening methods2.  The current standard of care includes chemotherapy 
treatment with carboplatin and paclitaxel with or without cytoreductive debulking 
surgery. Initial treatment with this chemotherapy regimen is effective in producing an 
expected response in 70-80% of patients1.  
Despite this initial treatment success, up to 75-85% of these patients will develop 
a recurrence of their cancer requiring additional treatment intervention1–3 and many of 
them will not survive it. Though traditional treatment with chemotherapy and 
cytoreductive surgery produces a promising initial response and sparks hope in many 
patients, the overall five-year survival rate for advanced stage (III or IV) epithelial 
ovarian cancer (EOC) remains less than 30%3.  Due to the extremely high rate of 
recurrence and lack of effective long-term treatment, recurrent ovarian cancer is viewed 
as a chronic disease2.  Unfortunately, current therapies are not an effective option for 
most patients and overall survival (OS) rates have remained largely unchanged for the 
past 3 decades3.  There is a tremendous need for therapies targeted at decreasing 
recurrence rates and sustaining remission, thereby increasing overall survival.  
Nutritional and lifestyle modifications have been broadly studied in the context of 
improving overall health and decreasing risk for illness such as cancer. The American 
Institute for Cancer Research estimates that diet, physical activity, and maintenance of 
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appropriate body weight can prevent up to 30-40% of all cancers4.  While it is becoming 
more widely accepted that these lifestyle changes can prevent development of disease, 
there is a lack of knowledge of what effect these changes can have on patients that 
already bear a cancer diagnosis.  Women undergoing treatment for ovarian cancer are left 
with limited options when traditional treatments fail and their cancer returns. While a 
cure is not yet readily available for patients suffering the diagnosis of this lethal disease, 
there is a need for research targeting dietary and lifestyle modifications specific to 
prevention of ovarian cancer recurrence.  
 
Statement of the Problem 
Healthy dietary habits, physical activity, and overall lifestyle contribute to our general 
health and help prevent illnesses such as heart disease, diabetes, and even cancer. 
Chemotherapy has been the mainstay of oncological treatment for years, with constantly 
improving regimens that strive to minimize toxicities and increase efficiency. While 
chemotherapy, radiation, and surgery remain the standard of care for many cancers, a role 
for nutrition and lifestyle intervention in the prevention of cancer has been suggested. 
Research in this area has focused on the impact of these modifications on primary 
prevention of malignancy. There seems to be a gap in knowledge of the effect of these 
lifestyle changes on prognosis of patients with a pre-existing cancer diagnosis. While 
chemotherapy improves prognosis and prolongs the lives of many cancer patients, it is 
rarely a cure, and patients are too often left with the impending threat of recurrence.  
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Advanced stage epithelial ovarian cancer frequently has a particularly promising 
response to initial treatment with chemotherapy and cytoreductive surgery. However, 
overall prognosis for these women remains poor. Attempts to improve outcomes for 
ovarian cancer patients have focused on primary prevention and early detection. With a 
lack of promising progress in this area, there is a need to focus on prevention of cancer 
recurrence.  In this instance, where primary treatment is not effective in sustaining 
remission or improving overall survival, could dietary and lifestyle modifications 
improve overall outcome and prevent ovarian cancer recurrence?   
 
Hypothesis 
Dietary and lifestyle modification for specific nutritional elements and weight reduction 
will reduce the rate of ovarian cancer recurrence.  
 
Objectives 
The objective is to identify specific nutrients associated with a reduction in ovarian 
cancer recurrence risk in patients diagnosed with advanced stage (III or IV) high-grade 
papillary serous ovarian cancer. The primary goal is to summarize the most recent data to 
be presented to providers in the format of a CME lecture. The goal of the lecture will be 
to provide Physician Assistants (PAs) and other health care professionals with the 
information necessary to recommend dietary and lifestyle guidelines for ovarian cancer 
patients to reduce their risk of cancer recurrence.   
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Specific Aims 
1. Identify specific nutrients and lifestyle interventions associated with 
decreased risk of epithelial ovarian cancer  
2. Summarize the current data on dietary and lifestyle recommendations to 
decrease risk of EOC 
3. Create a Continuing Medical Education lecture with the goal of providing 
Physician Assistants with information on the most recent updates on lifestyle 
interventions in the prevention of EOC 
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REVIEW OF THE LITERATURE 
Overview 
 
Epidemiology  
Ovarian cancer is the leading cause of gynecologic cancer death in women5.  In the 
United States, an estimated 22,280 new cases of ovarian cancer are diagnosed annually 
and the projected number of deaths from this disease in the year 2016 is 14,2406.   The 
predicted overall five year survival for all types of ovarian cancer is approximately 
46.2%7, but this number varies significantly based on histological type, grade, and stage 
at diagnosis.  For patients with localized stage I cancer at diagnosis, the five year survival 
is approximately 92.1%, while the survival for patients with stage III or IV cancer which 
has spread outside the ovary and regional lymph nodes drops to just 28.8%7.  
Unfortunately, ovarian cancer rarely presents with specific symptoms, and many of these 
cases are not diagnosed until they have already reached a late stage and therefore carry a 
poorer prognosis.  The difference in survival rates at a localized early stage diagnosis 
compared to a late stage at presentation highlights the importance of early detection and 
preventive measures.  
The overall lifetime risk of development of ovarian cancer for the general 
population is approximately 1.3% and the average age for a woman at initial diagnosis is 
60 years old8.  While many risk factors have been suggested for the development of 
ovarian carcinoma, the strongest risk is associated with a family history, with 
approximately 10% of patients exhibiting an inherited genetic predisposition8.  The 
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greatest of the genetic risks is associated with the presence of mutations in the BRCA1 
and BRCA2 genes9. The average risk of developing ovarian cancer for a woman with a 
BRCA1 mutation is 39%, while the risk for a woman with a BRCA2 mutation is 11%10.  
A 1.5-2 fold increased risk for development of ovarian cancer has been observed with 
infertility, nulliparity, and late or early menopause9. Oral contraceptive use, multiparity, 
hysterectomy, and tubal ligation have been found to be protective against the 
development of ovarian neoplasm9.   
Surface epithelial ovarian cancer (EOC) is the most frequently diagnosed ovarian 
malignancy. High grade serous carcinoma (HGSC) is the most common EOC, accounting 
for 70% of all surface epithelial carcinomas diagnosed in North America5.  Due to its 
aggressive nature, HGSC accounts for 90% of the surface epithelial cancers that present 
with stage III or stage IV disease and is responsible for the majority of deaths due to 
ovarian cancer11.   
With a lack of specific symptoms and effective screening, most women are not 
diagnosed until they present with advanced-stage disease.  Current screening for primary 
ovarian carcinoma includes trans-vaginal ultrasound and Cancer Antigen 125 (CA125) 
biomarker detection. However, neither of these techniques have been found to reduce 
morbidity or mortality3 and the survival rates have remained unchanged.  
	7 
	
Figure 1. Overall survival rate in patients with epithelial ovarian cancer by histologic 
grade, Karimi-Zarichi, et al. (2015) 12 
In the above Kaplan Meyer curve by Karimi-Zarichi et al, the OS for ovarian cancer 
patients is shown over a time course in months. OS is greatest for Grade 1 disease, 
followed by Grade 2, Grade 3, and finally Grade 4 presenting with the worst overall 
survival.   		
Pathophysiology 
Although ovarian cancer is often thought of as a single entity, it is more accurately 
described as a group of heterogeneous diseases, each with its own risk factors, 
presentation, natural history, and response to treatments. Epithelial ovarian carcinoma 
(EOC), which includes serous, endometrioid, clear-cell, and mucinous types, accounts for 
approximately 90% of all ovarian neoplasms 13. Among the epithelial neoplasms, serous 
carcinoma is the most common and will be the focus of this literature review. Serous 
carcinoma is further divided into two sub-classifications, High Grade Serous Carcinomas 
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(HGSC) and Low Grade Serous Carcinoma (LGSC).  These two subtypes differ greatly 
with regards to their pathology and pathophysiology and have been found to develop and 
progress via two distinct pathways (Figure 2)14.  
The LGSCs follow what is now known as the Type I pathway.  Type I ovarian 
cancer includes low grade serous carcinoma, endometrioid carcinoma, mucinous 
carcinoma, and clear cell carcinomas15.  Type I low grade serous carcinomas have been 
found to develop from precursor adenofibromas or borderline tumors and progress to 
serous carcinoma through a somewhat predictable and step-wise manner14.  Via this Type 
I pathway, a serous cystadenoma or adenofibroma slowly progresses to an atypical 
proliferative serous tumor (APST) then to a non-invasive macropapillary serous 
borderline tumor (MPSC), and finally to an invasive MPSC14.   The identifiable precursor 
lesions and the relatively slow, step-wise pattern of development often allow low grade 
serous tumors to be detected and diagnosed at a relatively early stage.  LGSC are also 
associated with a certain group of genetic mutations.  Specifically, they frequently exhibit 
mutations in the KRAS, BRAF, PTEN, and CTNNB115 and generally lack mutations of 
TP5314.  Tumors that progress along the Type I pathway present with low-grade nuclei 
with infrequent mitotic figures14.  The differences in genetic mutations, precursor lesions, 
and mitotic figures may provide some explanation as to why these tumors behave so 
differently than High Grade Serous Carcinomas of the ovary.  
Ovarian High Grade Serous Carcinomas (HGSC) are thought to develop via what 
is known as the Type II pathway. Unlike the adenofibroma of LGSC, a consistent 
morphologically identifiable precursor lesion of HGSC has been more difficult to verify 
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and the tumors have long been thought to arise de novo. However, there is mounting 
evidence to suggest that many of these HGSCs actually develop from intraepithelial 
carcinoma in the fallopian tube and therefore are not in fact strictly of ovarian origin14.  
While a morphologically identifiable precursor lesion for HGSC has not been 
recognized, it is becoming increasingly more accepted that many of these carcinomas 
may in fact arise from very early lesions in the fallopian tube known as tubal 
intraepithelial carcinomas (TIC)14.  These lesions are found at the fimbriated end of the 
fallopian tube, in close proximity to the ovarian surface. Increasing evidence suggests 
that TICs may be the origin of at least a subset of these high grade malignancies. First, in 
women with BRCA mutations but no evidence of ovarian cancer undergoing prophylactic 
salpingo-oophorectomies, early serous carcinomas have been detected in the fallopian 
tube with no evidence of tumor in the ovary itself. Second, 92% of TICs contain an 
identical TP53 mutation as that seen in ovarian high grade serous carcinoma. Third, p53 
is expressed in small foci of histologically normal epithelium, termed the p53 signature. 
It is thought that this p53 mutation leads to TIC, which ultimately progresses to HGSC of 
the ovary 14. While it is possible that these tubal intraepithelial carcinomas may actually 
be metastases from a primary ovarian cancer, TICs have been found to have shortened 
telomeres compared to HGSC. These shortened telomeres are an early sign of 
carcinogenesis leading to chromosomal instability, which is a key trait of HGSC 16, 
suggesting that the TIC develops prior to HGSC.   
Type II HGSC are clinically aggressive and often not discovered and diagnosed 
until they have already reached an advanced stage15. The progression of HGSC is rapid 
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with characteristic high grade nuclei and numerous mitotic figures 14.  The common 
mutations of KRAS, BRAF, or ERBB2 seen in LGSC are uncommon in HGSC, but TP53 
mutations are seen in 80%, indicating a significant genetic difference between the two 
types of serous carcinomas. Additionally, germline mutations of BRCA1 or BRCA2 are 
found in 15% of all serous carcinomas in North America, and are much more frequently 
noted in HGSC than in LGSC14.  Both BRCA and TP53 serve a tumor suppression 
function and therefore mutations in these genes allow for development of tumor activity 
and carcinoma progression.  The increased likelihood of BRCA mutations in Type II 
ovarian cancer correlates with an increased risk for hereditary breast and ovarian cancer 
(HBOC)15.  
The type I and type II pathways described are generally thought to be mutually 
exclusive, each following a distinctly different natural progression and resulting in unique 
presentations of disease. However, there is a possibility that a small subset of HGSC 
(type II) may actually arise from LGSC (type I). In a study carried out at Johns Hopkins 
Hospital, 3% of all serous carcinomas contained components of both high and low grade 
serous carcinoma17. Of the tumors with shared components, none of them contained a 
mutation of TP53, the mutation commonly seen in typical high grade serous 
carcinomas17. The lack of TP53 mutation suggests that the HGSC may have actually 
evolved from LGSC, a carcinoma that commonly lacks TP53 mutations14, rather than 
from the type II pathway traditionally seen in HGSC.  
LGSC and HGSC, arising from separate precursors and evolving via different 
mechanisms, present very different prognoses for patients. LGSC, developing via the 
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Type I pathway is typically composed of slow growing tumors and therefore often 
present at an earlier stage, where early intervention can occur.  In contrast, HGSC 
typically presents with rapidly progressing aggressive tumors and patients are generally 
not diagnosed until late stage, where intervention is less effective. Unfortunately, the 
majority of all serous ovarian cancers are of the high-grade type, where treatment options 
for recurrent disease are limited and information is sparse on how to prevent recurrence.  
In the instance of low-grade serous carcinoma, where a precursor lesion can be 
identified and genetic mutations can be targeted, early treatment provides for a much 
better prognosis for many women. However, in the instances of HGSC, where genetic 
mutations are not identified and a precursor lesion cannot be detected early in the clinical 
course, there is a need for additional targets of therapy.  
	
Figure 2, Shih et. Al (2004).18 Schematic representation of the dualistic model 
depicting the development of ovarian serous carcinomas, the most common type of 
ovarian cancer. 18 		
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Treatment 
The current treatment of primary ovarian cancer most often consists of a combination of 
cytoreductive surgery with a carboplatin and paclitaxel based chemotherapy regimen19.  
Cytoreductive surgery is performed with the goal of achieving no gross residual disease 
post-operatively. It has been demonstrated that a visibly disease-free outcome after 
surgery is a more significant prognostic indicator of survival than degree of metastasis 
prior to surgery20.   Patients with high grade serous carcinoma typically have a promising 
response to chemotherapy treatment, with 70-80% exhibiting an expected initial 
response1.   
Recurrence of ovarian carcinoma following initial treatment is often difficult to 
detect. Patients reported to be in remission are generally asymptomatic, living high 
quality lives.  Similarly to the presence of primary ovarian cancer, recurrence often 
presents with only vague abdominal symtoms2. Due to the lack of specificity of the 
physical symptoms, recurrence is frequently detected clinically via CA125 measurement 
or CT scans prior to the patient noticing any changes2.   
Treatment options for recurrence of ovarian cancer are often dependent upon the 
level of platinum sensitivity. Platinum sensitivity is defined as having a platinum-free 
interval (time between the last dose of platinum-based chemotherapy and evidence of 
cancer progression) of greater than or equal to 6 months. If the platinum-free interval is 
less than 6 months, the cancer is considered to be platinum resistant13.   It has been found 
that treatment of recurrent ovarian cancer with paclitaxel plus platinum-based 
chemotherapy improves survival and progression-free survival compared to conventional 
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platinum-based therapy21.   For patients who no longer respond to platinum-based 
chemotherapy, treatment choice should consider patient preference, toxicity profile, ease 
of administration, and availability19.  Single treatment regimens with paclitaxel, 
topotecan, or pegylated liposomal doxorubicin should be considered as they have shown 
to be reasonably effective in patients demonstrating platinum-resistance19   
	
Clinical Course  
More than 80% of patients with advanced stage ovarian cancer will experience recurrence 
of their cancer at some point after initial treatment13 and will require additional therapy2.  
Patients whose recurrence presents as isolated metastatic cancer that can be fully resected 
with an additional cytoreductive surgery have a better prognostic outcome. 
Unfortunately, this presentation is rare13.  Due to the lack of effective options, treatment 
of patients with recurrent epithelial ovarian cancer is now viewed by physicians as 
management of a chronic disease2.   
Despite the extremely high recurrence rate, an effective screening measure to 
identify relapse of ovarian cancer and improve outcomes for these patients does not yet 
exist.  The most frequently identified initial sign of ovarian cancer recurrence is an 
increase in CA-125 serum level. It is a glycoprotein that serves as a biomarker for ovarian 
cancer.  An increase in CA-125 level can be seen approximately 2 to 6 months before 
cancer recurrence is detectable via imaging studies or before the patient becomes 
symptomatic22.  
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However, the recommendation on how often to monitor this biomarker varies 
depending on the source.  According to the Society of Gynecologic Oncology (SGO), a 
review of clinical symptoms and physical examination of patients following initial 
treatment for ovarian cancer should be completed every 3 months. If there is clinical 
suspicion of recurrence, an optional CA125 test and CT, PET, or MRI imaging should be 
perfeormed23.  The National Comprehensive Cancer Network (NCCN) guidelines 
recommend follow-up visits every 2-4 months for 2 years with routine measurement of 
CA125 levels and additional radiographic imaging in cases where recurrence is 
suspected24.    
While CA-125 levels allow for detection of possible recurrence earlier than 
presentation of symptoms or detection of disease via imaging studies, it is not clear if 
treatment based solely on elevation of CA-125 is justified. Treatment in asymptomatic 
women with a detected elevation in CA-125 has not been found to significantly impact 
survival22. In a study conducted by the European Organization for Research and 
Treatment of Cancer, women in clinical remission were randomized to treatment either 
based on detection of elevated CA-125, or after the onset of symptoms. It was found that 
there was no significant improvement in survival regardless of if treatment was initiated 
immediately following CA-125 detection or following onset of symptoms22. Thus, while 
it allows earlier detection for ovarian cancer recurrence, CA-125 elevation may not hold 
much value in improving survival in patients with recurrent cancer. This suggests that 
recurrence of ovarian cancer carries an overall poor prognosis, regardless of when 
treatment is initiated.  
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The high recurrence rate, ineffective screening measures, and limited treatment 
options for recurrence all reinforce the need for development of new therapies and 
techniques focused on maintenance of progression-free survival (PFS). Dietary and 
lifestyle interventions have been studied in the context of prevention of primary 
development of cancer, but there is a gap in the knowledge of how these interventions 
impact the prognoses of patients post-diagnosis. A universally recommended guideline 
outlining specific nutritional components to optimize patients’ diets to prevent the 
recurrence of cancer may be the next step in improving the clinical course of ovarian 
cancer.  
 
Prevention 
Known risk factors for ovarian cancer, as mentioned previously, include family history, 
nulliparity, infertility, hormone replacement therapy, and early or late onset of 
menopause. For women with a genetic predisposition or with the presence of a precursor 
lesion in the fallopian tubes, prophylactic salpingo-oophorectomies are available to 
reduce the risk of ovarian cancer development.  The Society of Gynecologic Oncology 
recommends that all women aged 35-40 who have germline mutations in high risk genes 
should undergo risk-reducing surgery25.  
For the general female population, however, prevention is typically aimed at 
avoidance of the known risk factors. It is believed that ovulation plays a role in ovarian 
carcinogenesis, supported by the significant reduction in ovarian cancer risk seen with the 
use of oral contraceptives as well as increased parity 16.  It has been proposed that 
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hemolyzed blood from retrograde menstruation and the release of follicular fluid during 
ovulation causes increased free radicals, predisposing to carcinogenesis16.  Therefore, 
ovulation suppression may have a protective effect against EOC development. 
Due to the heterogeneity of ovarian cancer as a disease, it is becoming 
increasingly evident that the treatment and management of these malignancies must be 
individualized in order to achieve the most effective outcome. Genomic Wide 
Association Studies (GWAS) have been carried out to compare the genotype frequencies 
of common variants seen in ovarian cancer throughout the genome15. Through these 
genomic studies, Single Nucleotide Polymorphisms (SNPs) have been identified that 
show an association with increased ovarian cancer risk.  If more of these polymorphisms 
can be identified, it would open a window of opportunity for prevention of recurrence via 
targeting specific genetic components and may have implications on the future of EOC 
treatment. 
 
Lifestyle 
An estimated 30-40% of all cancers can be prevented by lifestyle and nutritional 
measures alone26. A healthy lifestyle includes a nutritional diet, physical activity, and 
maintenance of a healthy weight. Given the poor prognosis and extremely high 
recurrence rate of ovarian cancer, there is a need to identify additional options for 
patients to reduce their risk of recurrence and increase progression free survival. While 
trials for new therapies continue to evolve, a lifestyle intervention that could potentially 
improve prognosis would be extremely valuable to patients currently suffering from this 
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disease. Unfortunately, the nutritional and lifestyle guidelines for ovarian cancer 
survivors are not well defined and can be confusing.  
There is a significant body of research on several different nutritional elements 
that may play a role in reduction of cancer risk. However, a universal guideline is not 
available to ovarian cancer survivors wishing to optimize their diets to minimize cancer 
recurrence risk. In this literature review, the goal is to compile a list of recommended 
nutrition guidelines for ovarian cancer patients in remission in order to decrease their risk 
of recurrence.  
Obesity remains a risk factor for much morbidity, including several types of 
cancers. Higher body weight has been positively associated with a higher death rate in 
esophageal, colon, rectal, liver, gallbladder, pancreatic, renal, gastric, prostate, breast, 
uterine, cervical, and ovarian cancer27. Several factors including genetics, sedentary 
lifestyle, and poor dietary habits contribute to the development of obesity.  
Increased physical activity is believed to be protective against many cancers. 
Little research has been done, however, on the impact of physical activity on long-term 
survival and prevention of cancer recurrence in ovarian cancer survivors. Several studies 
have supported the hypothesis that obesity and hormone replacement therapy increase the 
risk for ovarian cancer while oral contraceptives decrease the risk28.  Physical activity, 
with the goal of maintaining a healthy body weight, may be protective against obesity 
and therefore reduce the risk of cancer.  
It has been proposed that energy balance of calorie intake and expenditure has 
implications on cancer risk. A positive energy state, with a high body mass index (BMI) 
	18 
and increased obesity has been associated with higher risk of development of many 
cancers. This positive energy balance promotes tumor growth by creating an environment 
that favors tumor-promoting factors. These modify growth signaling, inflammation and 
angiogenesis29, making an ideal environment for tumor development and growth. High 
levels of insulin and insulin growth factor (IGF-1) increase the risk of cancer 
development and serve as a poor prognostic factor29. The insulin-insulin growth factor 
pathway activates downstream signaling to lead to the activation of the 
phosphatidylinositol-3 kinase/Akt-mTOR (P13K/Akt) pathway, regulating cell survival 
and proliferation. The PI3K/Akt pathway is commonly activated in all cancers29.  
Therefore, a diet that restricts the amount of insulin released, thereby reducing the extent 
of activation of the PI3K/Akt and similar pathways may reduce cancer risk and improve 
prognosis for patients with cancer. An increased activation of these pathways has been 
found in high-energy diets and decreased activation seen in calorie restricted diets29, 
suggesting a protective role of calorie restriction.  
Over-consumption of calories has been positively associated with cancer risk, 
while Calorie Restriction with Optimal Nutrition (CRON) has been found to inhibit 
tumor growth 26. CRON emphasizes a reduction in the total amount of calories consumed 
by about 20-30% of the amount required to maintain a “normal” bodyweight while still 
emphasizing necessary amounts of vitamins, minerals, and other nutrients. Therefore, the 
CRON diet does not simply restrict all calories, but restricts excess calories, while 
maintaining necessary healthy nutrients.  
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Furthermore, it is possible that a calorie restriction diet alone provides anti-cancer 
benefits, regardless of nutritional content. Women with anorexia nervosa, exemplifying a 
low caloric intake as well as decreased nutrient intake, have been found to have a lower 
incidence of breast cancer26, suggesting that perhaps a low calorie diet is sufficient in 
decreasing cancer risk regardless of the quality of nutrients consumed. It is possible that a 
low-calorie diet is protective against insulin resistance. Obese individuals often have 
increased levels of insulin and IGF-1 in their blood, a phenomenon known as 
hyperinsulinemia or insulin resistance. In addition, obesity also predisposes to an 
increased amount of estrogen, due to high production of this hornome in fat tissue. 
Estrogen has been associated with several types of cancers, including breast cancer and 
some types of ovarian cancer. While a high-energy diet is associated with 
hyperinsulinemia and increased estrogen production predisposing to cancer, calorie 
restriction and reduction in body fat, as seen in women with anorexia nervosa, seems to 
create a hostile environment for tumor development.  
While a low-calorie diet is thought to effectively starve tumor cells and therefore 
decrease tumor growth and development of cancer, it is important to recognize specific 
nutritional elements that put people at particular risk for tumor growth as well as 
elements that appear to be protective. Cancer development has been associated with 
alterations in cell metabolism. A commonly recognized property of cancer cells is their 
ability to utilize glucose at especially high rates30. Hexokinase is the enzyme involved in 
converting dietary glucose to glucose-6-phosphate. It has been found that hexokinase has 
increased activity in cancer cells via an increase in the gene copy number of the 
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enzyme30. With an increased amount of hexokinase working to utilize glucose to promote 
cancer cell growth, malignant cells have developed a proliferation strategy supported by a 
diet high in glucose-rich foods. The enzyme is activated by glucose, insulin, hypoxic 
conditions, and phorbol esters. Therefore, ingestion of sugary foods feeds the metabolic 
strategy of cancer cells, favoring rapid proliferation and prolonged survival30.  
Concentrated sugars and refined flour products further impair normal glucose 
metabolism. Glycemic index (GI), which takes into account the blood sugar response to a 
standardized amount of carbohydrate in a certain food, and glycemic load (GL), which 
additionally accounts for the amount of the food eaten, have been positively associated 
with cancer development26.  The higher the glycemic index of a certain food, the more 
insulin is released as a response to increase in blood sugar. Therefore, a high GI increases 
the levels of insulin and IGF-1, predisposing to hyperinsulinemia. Ovarian cancer has 
been directly associated with dietary glycemic index, suggesting a possible role of 
hyperinsulinemia and insulin resistance in ovarian cancer development31. Therefore, there 
may be a role in insulin-sensitizing agents similar to those encouraged in a diabetic diet 
in cancer patients. 
Resveratrol, an insulin sensitizer, has been found to interrupt glucose metabolism 
in specific cancer cells32.  It has selective cytotoxicity for ovarian cancer cells through 
glucose metabolism regulation via regulation of glucose transporter 1 (GLUT1), which is 
overexpressed in ovarian cancer32.  A study performed by Gwak et all found that 
resveratrol inhibits GLUT1 transport to the plasma membrane, therefore impairing 
glucose uptake and inducing apoptosis32. This data suggests that the phytochemical 
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resveratrol, found in fruits such as blackberries, blueberries, and red grapes may have a 
role in prevention of ovarian cancer development via interruption of glucose metabolism.  
 Much of the research in the area of nutrition and oncology has included the role of 
antioxidants and free radicals in the progression of carcinogenesis. Free radicals are 
created during the transfer of energy when an atom or molecule either gains or loses an 
electron. This happens naturally as a byproduct of normal human processes, but causes 
damaging oxidative stress in high concentrations. Reactive oxygen species (ROS) created 
in this process damage nucleic acids, amino acids, and other cellular components 
predisposing to cancer development33. These are neutralized naturally by the body’s 
antioxidant system, which consists of enzymes and other compounds33. Antioxidants 
work to inhibit oxidation, or the loss of an electron, thereby decreasing the amount of free 
radicals created.  
Many foods contain antioxidant properties and may help prevent carcinogenesis 
by minimizing free radicals when they reach dangerous concentrations. Dietary 
antioxidants have been found to be useful in supplementing the effects against 
carcinogenesis caused by arsenic33. This concept may be generalizable to other types of 
cancers affected by free radicals and ROS and may hold value in the prevention of 
ovarian cancer. More research is needed in the area of antioxidants and ovarian cancer 
specifically, but several antioxidant-containing foods have been associated with 
decreased cancer risk.  
In addition to their resveratrol content and effects on glucose metabolism, red 
grape seeds and skins contain beneficial antioxidants. They are thought to have 
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anticancer activity through a wide range of mechanisms. These antioxidants specifically 
target epidermal growth factor receptor (EGFR) and its downstream pathways, inhibiting 
over-expression of COX-2 and prostaglandin E2 (PGE2) receptors, as well as modifying 
estrogen receptor pathways, resulting in cell cycle arrest and apoptosis. This function in 
prevention of replication and resultant apoptosis could allow for targeted limitation of 
rapidly dividing malignant cells, suggesting a role of red grape products in the reduction 
of cancer occurrence.  
Fruits and vegetables provide countless health benefits. It remains controversial, 
however, whether a diet high in fruits and vegetables has a significant impact on ovarian 
cancer risk specifically. Several studies have failed to show an association, while others 
have suggested a possible relationship but remain inconclusive. It may be that certain 
vegetables are beneficial in preventing ovarian cancer while others fail to have an effect. 
It has been proposed that increased intake of yellow and cruciferous vegetables, such as 
broccoli, brussel sprouts, and collard greens, as well as carotenoid-containing vegetables 
improve survival in ovarian cancer patients.  
Carotenoids are known for providing health benefits via antioxidant properties, 
inhibition of malignant tumor growth, and induction of apoptosis34.  A high intake of 
foods containing carotenoids has been associated with reduced risk of breast, cervical, 
ovarian, and colorectal cancers34. They can be found in foods such as carrots, spinach, 
bell peppers, kale, and several other vegetables. The major carotenoids that seem to have 
the greatest antioxidant effect include B-carotene, lycopene, lutein, zeaxanthin, crocin, 
and curcumin34.  A significant increase in both alpha and beta carotenoids has been 
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associated with a diet composed of low fat, high fiber, encapsulated fruit and vegetable 
juice concentrates, and a soy-based beverage35. Their antioxidant activity inhibits cell 
growth and malignant transformation and may be associated with improved prognosis 
among ovarian cancer survivors35.  
The poor prognosis of patients with advanced EOC is attributed in large part to 
the late stage at diagnosis and the tendency for early metastasis even prior to diagnosis. 
Hens have been found to closely model the human response to ovarian cancer. Hens fed 
flaxseed-rich diets have a significant reduction in ovarian tumor severity, with more 
tumors confined to the ovary and decreased metastatic spread36. Flaxseed contains omega 
3 fatty acids (OM-3FA) and phytoestrogen lignans, which have anti-inflammatory, anti-
cancer effects 36. OM-3FAs and phytoestrogen lignans target the inflammatory 
prostaglandin pathway, most notably PGE237. Ovarian cancer has a significantly better 
outcome at early stages with containment to the ovary and decreased metastatic spread. If 
flaxseed can reduce ovarian tumor severity and metastasis, it opens the possibility of 
treating more women in an early stage of cancer, thus improving their prognosis 
significantly. Additionally, there could be a role of flaxseed in preventing ovarian cancer 
recurrence at more distant sites, favoring a more localized presentation and therefore a 
better prognostic outcome.   
Vitamin D deficiency has a potential role in promoting development of many 
different types of cancers. Conversely, higher Vitamin D levels may improve overall 
prognosis of ovarian cancer patients. It has been found that higher serum 25-
Hydroxyvitamin D (25(OH)D) concentrations at the time of diagnosis of ovarian cancer 
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are associated with increased survival, independent of other prognostic factors such as 
age, stage, and post-operative residual disease38. Increased intake of Vitamin D was 
found to be strongly inversely associated with serous borderline and endometrioid tumors 
in particular39.  More research is needed to determine a direct effect of Vitamin D on 
serous tumor development, but vitamin D supplementation may improve survival 
outcomes for women with all types of ovarian cancer. 
The effect of dairy products on cancer development has been controversial. Some 
studies have suggested an increased risk of cancer associated with high dairy intake while 
others have proposed an inverse relationship. One study found that high intake of certain 
dairy foods is in fact associated with increased ovarian cancer risk while others 
demonstrate a protective property against ovarian carcinoma. In particular, it was 
observed that intake of skim/low fat milk, yogurt, and cheeses decreased ovarian cancer 
risk while whole milk and cream cheese increased risk39.  When the specific components 
of dairy nutrients were examined, calcium was found to have a strong inverse association 
with ovarian cancer risk overall, with a particularly strong effect on decreasing risk of 
serous borderline and mucinous tumors. More studies are needed to determine a possible 
effect of these two components on high-grade serous carcinoma risk.  
In addition to their role in direct prevention of cancer, there may be a role of 
certain foods in promoting chemo-sensitivity. Often times, recurrent ovarian cancer 
presents with platinum-resistant disease. There is mounting evidence that certain 
nutritional elements may have sensitizing effects on chemotherapy drugs, amplifying 
response. One study isolated individual cranberry flavonoids to examine their effect on 
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ovarian cancer cells.  Two flavonoids with the most promising results were quercetin 
aglycone and cranberry A-type proanthocyanidins (PACs).  Poly (ADP-ribose) 
polymerase (PARP) is a family of enzymes involved in DNA repair. When DNA damage 
is severe, such as in cancer cells, PARP translocates apoptosis inducing factor (AIF) from 
the mitochondria to the nucleus, increasing the apoptotic threshold and favoring cancer 
cell survival40. Pharmacologic inhibition of PARP has been proposed as a therapy option 
for several types of cancers40.  Treatment of ovarian cancer cells with quercetin aglycone 
and PAC DP-9 led to the induction of increased apoptosis, causing caspase-3 activation, 
PARP deactivation, and amplification of cisplatin antitumor activity 41. Therefore, dietary 
flavonoids, particularly quercetin aglycone and cranberry A-type proanthocyanidins, 
seem to be protective against ovarian cancer and may have potential to prevent 
recurrence.   
Table 1.  Nutritional Elements and Ovarian Cancer Risk  
Protective Factors  Risk Factors  
Flavonoids Red and processed meat 
Cruciferous vegetables  High glucose diet 
Calorie restriction High calorie diet  
Flax seed Obesity 
Carotenoids Concentrated sugars 
Vitamin D High fat diet  
Fiber Refined flour products  
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Table 1. Nutritional Elements and Ovarian Cancer Risk. Table 1 summarizes 
some of the proposed nutritional elements and their effects on ovarian cancer risk. Both 
protective factors and risk factors for development of ovarian cancer are listed.  
 
Existing research 
Obesity has been studied extensively in the context of cancer risk. It has been found to be 
associated not only with an increased risk of developing cancer but also with an increased 
risk of death from various cancers. One prospective study found that women with a BMI 
greater than or equal to 40 had a relative risk of dying from cancer of 1.62, with a 95% 
confidence interval 1.40-1.8127. In women with ovarian cancer, those with a BMI of 35.0-
39.0 had a relative risk of death from their cancer of 1.51, compared to women with a 
BMI 18.5-24.9, with a 95% confidence interval, 1.12-2.0227.   
It is thought that a positive energy balance, or excess intake of calories, promotes 
tumor growth and thus predisposes to cancer development, while a negative energy 
balance with caloric restriction delays cancer progression.  One study showed that a 
positive energy state attained by a fat-rich diet encouraged an aggressive ovarian cancer 
growth pattern, while a negative energy state achieved by a 30% calorie restriction diet 
resulted in limited and restrained ovarian cancer growth pattern in vivo in mice29. Mice 
were injected with ID8 cells to generate ovarian tumors and the differences in tumor 
progression were analyzed between a group fed a regular diet (RD), a high energy diet 
(HED), and a calorie restriction diet (CRD)29. They found that the mice in the HED had a 
significantly higher number and size of tumor nodules in the diaphragm and bowel 
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compared to those in RD and CRD, while the CRD mice had the lowest overall tumor 
burden (p<0.001)29.  
 A calorie restriction diet, on the other hand, has been found to have an inverse 
relationship with tumor development. In an observational cohort study, O’Brien, et. al 
(2016) found that women with a history of an eating disorder were less likely to develop 
breast cancer than women who had never had an eating disorder (HR=0.62, 95%CI: 0.42-
0.92)42.  Women with a past diagnosis of anorexia nervosa have a history of following an 
extreme calorie-restriction diet. This supports the idea that calorie restriction may indeed 
be protective against breast cancer, and may have implications on other types of cancer as 
well.    	
There may be a role of hyperinsulinemia in promotion of cancer development. A 
case-control study conducted in Italy analyzed the effect of glycemic index (GI) and 
glycemic load (GL) on ovarian cancer risk. They studied 1031 women with epithelial 
ovarian cancer with a median age of 56 and compared them to a control group of 2411 
women with a median age of 57 years with no history of cancer. Using a questionnaire to 
assess dietary habits, they determined that ovarian cancer was directly associated with 
dietary glycemic index (OR 1.7, 95% CI 1.3-2.1) and with glycemic load (OR= 1.7, 95% 
CI 1.3-2.1)31. Therefore, foods with high GI, such as sugary and fatty foods, which 
increase insulin response to blood sugar and predispose to hyperinsulinemia, increase risk 
of ovarian cancer. Women diagnosed with ovarian cancer should be urged to avoid food 
with a high glycemic index in order to prevent progression and recurrence of their 
disease.  
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A study conducted to determine the outcomes of three different dietary styles 
examined women with different nutritional habits to determine the effect on ovarian 
cancer risk. The three groups were defined as “meat and fat”, which included women 
who reported high consumption of processed meat, eggs, fat spreads, and sweets, “snacks 
and alcohol”, which included women with high consumption of alcohol, pizza, nuts, and 
other snacks, and “fruit and vegetable”, with high consumption of fruits, veggies, and 
whole-grains43.  The women with a diet high in red meats, processed meats, and fat had a 
2.5 fold increased risk of ovarian cancer43. The same study found a 40% lower risk of 
ovarian cancer in women in the  “snack and alcohol” diet. After adjusting for 
confounders, the protective effect of the snack and alcohol diet was ultimately attributed 
to an inverse relationship of red wine consumption with ovarian cancer risk43. This 
supports the hypothesis that flavonoids and resveratrol found in red wine reduce ovarian 
cancer risk.   
The antioxidant properties of foods containing a large amount of carotenoids have 
been found to be protective against EOC risk. A case-control study conducted in China 
by Zhang et al found a significant inverse association between intake of specific 
carotenoids and ovarian cancer risk. They examined 254 patients with EOC confirmed by 
histology and 652 age-matched controls. They compared the highest vs. lowest quartile of 
intake for alpha-carotene, beta-carotene, beta-cryptoxanthin, lutein, and zeanthin, and 
total carotenoids. Results supported a lower incidence of ovarian cancer for the highest 
quartile of all carotenoids; alpha carotene (OR 0.39, 95% CI 0.23-0.66), beta-carotene 
(OR 0.51, 95%CI 0.31-0.84), beta-cryptoxanthin (OR 0.51, CI 95% 0.31-0.84), lutein and 
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zeanthin (OR 0.45, 95%CI 0.27-0.76), and total carotenoids (OR 0.33, 95% CI 0.20-
0.56)44.  
Flax seed, which has an inherent antioxidant property, has been found to 
significantly impact the risk of EOC development, showing involvement in restricting 
ovarian tumors to more localized presentation. Eilati et al studied hens fed a flaxseed-
enriched diet and compared them to a control group to analyze for ovarian cancer risk. In 
the 3.5 year old hens, 50% of those fed a control diet developed ovarian cancer, while 
only 20% of those fed a flaxseed enriched diet developed ovarian cancer (p<0.05)37.  
Additionally, hens in the control group were more likely to develop late stage (T3 and 
T4) tumors, presenting with ascites and metastases, than the group fed a flaxseed rich 
diet37. The protective property of flaxseed in ovarian cancer risk seems to be largely tied 
to its ability to decrease levels of PGE2. In the hens studied by Eilati et al, PGE2 
concentration was significantly decreased in cancerous ovaries in hens fed flaxseed 
enriched diets than in those fed a control diet (p<0.001)37. Increased dietary flaxseed 
seems to have a protective effect on ovarian cancer risk, a property that may be attributed 
to its ability to decrease concentrations of the inflammatory agent PGE2.  
The association between circulating 25(OH)D and ovarian cancer risk has not 
been well defined. Zheng et al performed a case-control study among seven prospective 
studies in order to evaluate this relationship. They found no statistically significant effect 
of circulating vitamin D levels and EOC risk. However, when stratified for individual 
factors, an inverse association between 25(OH)D and ovarian cancer risk was suggested 
for women with a BMI >25kg/m2 (p<0.01)45, suggesting that there may be a role of 
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increased vitamin D concentration in preventing ovarian cancer in overweight women. 
Webb et al examined the effect of serum 25(OH)D concentration on overall survival of 
women with ovarian cancer. It was found that at diagnosis, higher serum 25(OH)D levels 
were associated with increased overall survival, with a HR 0.93, 95% CI 0.88-0.99 per 
10nmol/L 25(OH)D)38. In addition to serving a protective factor against ovarian cancer 
risk in overweight women, vitamin D levels may also prolong ovarian cancer survival 
rates.  
A longitudinal follow up study by Dolecek et al analyzed the effect of pre-
diagnosis diet on survival among 341 women diagnosed with EOC. They found that 
higher vegetable intake in general was associated with longer survival (HR 0.66, 95% CI 
0.43-1.01, p<0.05)46. Additionally, when analyzed specifically for yellow and cruciferous 
vegetables, survival was significantly better with increased intake. Higher meat intake, 
particularly red and processed meats, was found to have an inverse association with 
survival (HR 2.28, 95% CI 1.34-3.89). Dolecek et al also examined the effect of dairy on 
long term survival and found that milk consumption to be associated with decreased 
survival (HR 2.15, 95% CI 1.20-3.84, p <0.05)46. Pre-diagnosis diet may therefore have a 
significant effect on the long-term outcomes of ovarian cancer patients, with a diet high 
in cruciferous vegetables improving survival and red meats and dairy products decreasing 
survival. More research is needed in this area on the effect of changing to a diet based on 
these findings to determine the effect of a post-diagnosis diet on recurrence rates and 
long-term survival.  	
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METHODS 
Study design 
A lecture-based curriculum on nutrition and lifestyle recommendations for patients with 
ovarian cancer will be developed and presented to Physician Assistants (PAs) and other 
health care providers working in primary care and oncology. A review of the most up to 
date findings on the effects of nutrition and lifestyle interventions on ovarian cancer will 
be summarized and presented to the audience. The goal is to educate providers on 
information about dietary and lifestyle modifications specific to decreasing risk of 
ovarian cancer development. The hope is for attendees of the lecture to leave equipped 
with the knowledge necessary to feel comfortable engaging in a conversation with 
patients about lifestyle modifications to reduce their risk of cancer recurrence. This 
curriculum will be presented at Continuing Medical Education (CME) conferences and 
offered for one hour of CME credit.  
 
Study population and sampling 
The lecture will be given as a CME course at both national and local conferences with the 
goal of a total of 200 attendees. Assuming an estimated attendance of 100 providers at the 
national conferences and 10 providers at each of the local conferences, the course will 
need to be offered at least one national conference and ten local conferences in order to 
reach the sample size goal. The information will be presented as a one hour long lecture 
directed toward health care providers at the level of PA, but will be available to 
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physicians, nurses, and other health care workers who are interested in acquiring 
information to provide their patients.  
 
Study variables and measures 
In order to assess the efficacy of this curriculum, all those in attendance will perform a 
pre-test and a post-test to quantify baseline knowledge and evaluate the amount learned 
during the lecture. The pre-test will consist of 15 multiple-choice questions and will be 
formatted as a digital response Turning Point style quiz. Each attendee will be provided 
with a clicker for response purposes upon entering the lecture hall. Answers to the pre-
test questions will not be provided. At the end of the lecture, the same questions will be 
presented to the audience for response. The goal is to achieve a passing score of 80% for 
the post-test. In order to achieve the passing score of 80%, participants will need to 
provide the correct answer to 12 of the 15 questions.  
 
Recruitment 
The lecture will be offered at CME national and local conferences and made available to 
all health care workers, particularly emphasizing the attendance of physician assistants 
working in a primary care or oncology setting. Information about when and where the 
course will take place will be available on the CME website. Institutions interested in 
hosting the lecture will be given a flyer with a brief outline of the course as well as the 
time and location the lecture will take place to email to health care employees to 
encourage attendance.  
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 There will be a sign in sheet located at the door to the lecture hall for all attendees 
to sign in. This will allow all health care providers to gain CME credit for their 
participation in this course. The CME credit as well as the unique opportunity to gain 
access to information regarding updates on nutrition and oncology will serve as incentive 
for attendance.    	
Curriculum 
The curriculum will take the format of an hour-long lecture accompanied by a 
PowerPoint presentation. The learning objectives (Table 2) will be presented at the 
beginning of the lecture and will highlight the key aspects of the course. They will serve 
as the outline for the talk and will provide the audience with the key take-away points. 
 
Table 2. Learning Objectives 
At the end of the lecture, the learner will be able to: 
1. Recognize the limited effective treatment options and poor prognostic outcome for 
women with type 2 advanced ovarian cancer 
2. Identify the proposed differences between the type 1 and type 2 pathways of EOC and 
recognize treatment differences.   
3. Apply the most recent data on dietary and lifestyle modifications and EOC to their 
clinical work 
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4. Create a provider-patient dialogue to educate patients about recommendations and 
guidelines pertaining to nutrition and lifestyle in the prevention of EOC recurrence  
5. Recognize the need for additional studies on type 2 EOC to solidify evidence pertaining 
to nutrition and lifestyle and the prevention of recurrence  
 
 
Presentation Outline:  
• Introduction to the epidemiology of ovarian cancer, focusing on poor prognosis of 
advanced stage disease  
• Description of the differences between type 1 and type 2 disease, with emphasis 
on the lack of treatment options for recurrent aggressive type 2 cancer 
• Overview of the current treatment options, including the chemotherapy regimen 
and cytoreductive surgery 
• Presentation of recurrence rates statistics and poor survival even after promising 
response to therapy 
• Outline of the most recent findings in nutrition and lifestyle and the role in 
prevention of ovarian cancer development  
• Reinforce the need for additional studies on the effect of nutrition on the 
prevention of recurrence in women previously diagnosed and treated for EOC  	
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Curriculum Assessment  
The pre and post-test will serve as the main assessment of the ability of the curriculum to 
meet the learning objectives. The pre-test will assess health care provider’s baseline 
knowledge on ovarian cancer and the role of nutrition and lifestyle on preventing cancer 
development. As mentioned previously, the pre-test will be administered to all people in 
attendance prior to the start of the PowerPoint lecture using the Turning Point clicker 
system. Similarly, when the lecture has been completed, the post-test will be 
administered to the audience using the clicker system. Additionally, the participants will 
be given a paper survey asking asked how the knowledge acquired during the session will 
change their current practice (with up to 3 concrete examples). The survey is to be turned 
in prior to exiting the lecture hall. 
 The content of the pre and post-tests will have basis in the learning objectives and 
will include questions on nutritional elements and their effects on ovarian cancer 
development.  The question topics are displayed in Table 3.  
Table 3. Question Topics 
1. Types of ovarian cancer  
2. Pathway of type 1 vs type 2 EOC  
3. Overall prognosis of ovarian cancer 
4. Five year survival for advanced stage EOC 
5. Chemotherapy regimen for EOC 
6. Outcomes of cytoreductive surgery  
7. Effect of BMI on ovarian cancer development  
8. Effect of obesity on cancer mortality rates 
9. Effect of flaxseed on development of EOC 
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10. Effect of carotenoids on development of EOC 
11. Effect of cruciferous vegetables on development of EOC 
12. Effect of red meats on development of EOC 
13.  Glucose metabolism in cancer cells  
14. Effect of dairy products on development of EOC 
15.  Extent to which audience feels comfortable discussing dietary and lifestyle 
interventions for cancer patients in their practice  
 
Study variables and measures 
The main measure of the competency of the lecture to provide useful information and 
effectively teach the attendees will be the pre and post-tests. A series of 15 questions will 
be presented for the pre-test to assess the baseline knowledge of the attendees. After the 
lecture has been completed, the same 15 questions will be presented again, with the goal 
of an increase in score to at least 80% correct for the audience in total.  The questions 
will be based on the learning objectives listed in Table 2 and will include the topics in 
Table 3.   
 In addition, the demographics of the audience will be recorded using a Turning 
Point survey. The survey will consist of three questions, listed in Table 4.  
Table 4. Audience Demographics Survey 
1. Which of the following most accurately describes your current profession? 
a. Physician Assistant 
b. Nurse Practitioner 
c. Physician 
d. Nurse 
e. Other 
2. Which of the following most accurately describes the specialty in which you 
currently practice? 
a. Primary care 
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b. Oncology 
c. Gynecology 
d. Other  
3. How many years have you been practicing medicine? 
a. less than 1 year  
b. 1-5 years 
c. 5-10 years  
d. more than 10 years 
 	
Data collection  
The pre-test will be presented directly prior to the initiation of the PowerPoint 
presentation and the post-test will be administered immediately following the conclusion 
of the presentation in order to include the maximum number of attendees in data 
collection. The responses from these tests will be recorded digitally using the Turning 
Point clicker system. The attendees will also be given a paper survey asking them how 
the knowledge they acquired during the presentation will change their current practices. 
The survey will have space for the attendees to provide 3 examples of this. The pre- and 
post- test scores will be examined, with the goal passing score of 80% (12 out of the 15 
questions correct).  
 
Data Analysis 
The mean of both the pre-test and the post-test will be calculated. The pre-test mean will 
reflect the baseline knowledge of the providers in attendance prior to the lecture on the 
material. The post-test mean will reflect the knowledge that the providers have on the 
topic following the lecture. The goal is to achieve an overall mean score of at least 80% 
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on the post-test. There is no goal mean score for the pre-test as it is a function of baseline 
knowledge.  
 A paired t-test will also be run comparing the mean of the pre-test to the mean of 
the post-test. This will allow us to interpret the improvement in knowledge from baseline. 
Because the baseline knowledge of the audience may vary significantly depending on the 
demographics of each particular lecture, there will not be a minimum anticipated value 
for score improvement. However, this value will be useful if the audience as a whole 
does not achieve the mean score goal of 80% on the post-test.  In that case, the paired t-
test will reflect whether or not the post-test results were significantly different from the 
pre-test results. If they are, then the audience knowledge improved from pre-lecture to 
post-lecture. However, it the paired t-test is not significantly different, the lecture did not 
provide an appropriate intervention to adequately improve the audience’s knowledge on 
the subject matter.  
 
Timeline and Resources  
In order for the curriculum to be presented at CME conferences to PAs, physicians, and 
other providers, it must be submitted to and approved for CME by the Accreditation 
Council for Continuing Medical Education (ACCME) and the American Academy of 
Physician Assistants (AAPA). We will anticipate that approval from ACCME will take 
12 to 18 months to be completed and the application for AAPA approval will take 3 
weeks. Applications to each will be submitted in the summer of 2017, with expected 
approval from both by fall of 2018. We anticipate it will take one year to present the 
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lecture at one national conference and 10 local conferences. The anticipated completion 
of data collection will be in the fall of 2019.   
 
Institutional Review Board 
The curriculum will be submitted to the Institutional Review Board (IRB) for approval 
for educational research.  
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CONCLUSION 
Discussion 
The majority of the research conducted on improving EOC survival has focused on early 
detection and primary prevention of the disease. Due to the presence of identifiable risk 
factors and known precursor lesions for Type 1 LGSC, these cancers have been the target 
of much of this research. However, Type 2 HGSC, with a lack of specific risk factors, a 
clinically aggressive course, and a worse prognosis, needs to be studied more extensively 
with regard to prevention of both initial development and recurrence to improve survival.  
The data on nutritional elements and prevention of ovarian cancer development 
may not be generalizable to all types of EOC. Because of the earlier presentation and 
more identifiable risks, women with LGSC may be easier to identify and recruit for 
research studies than those with aggressive HGSC. Additionally, many of the dietary and 
lifestyle changes described in the literature focus on modulating estrogen levels, which 
may not play a significant role in some types of ovarian cancer, but not HGSC 
specifically.  Thus it is not clear whether these data are generalizable to both women with 
LGSC and those with HGSC. More studies are needed examining the effects of these 
interventions, specifically in HGSC.  
Additionally, much of the research that has been published focuses on nutritional 
components and the prevention of primary development of ovarian cancer. While this is 
clinically useful in the general population and in women at risk for developing EOC, the 
implication on patients who already have disease is not clear. There is a need for 
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additional studies focusing on the effect of these interventions on recurrence rates in 
women with previously diagnosed and treated HGSC in clinical remission.   
Summary 
Ovarian cancer is the leading cause of gynecologic cancer death in women. With an 
overall five-year survival rate of less than 30%, the diagnosis of stage III and IV EOC 
carries a poor prognosis and aggressive clinical course. Given the poor prognosis and 
high recurrence rate for women diagnosed with advanced stage EOC, there is a need for 
additional treatment interventions focusing on increased survival for this population. In 
particular, type 2 HGSC presents with clinically aggressive, difficult to treat disease with 
limited therapeutic options for recurrent disease. A dietary intervention to reduce ovarian 
cancer recurrence and increase overall survival would be extremely valuable in this 
population. 
Cruciferous vegetables, carotenoid-containing foods, flavonoids, flaxseed, and 
other antioxidants have been the subject of many studies researching the effect of 
nutritional components on ovarian cancer development. Additionally, obesity has been 
directly associated with ovarian cancer development as well as mortality. There is a broad 
range of potential foods, nutritional elements, and lifestyle factors that have been 
proposed to be effective in reduction of ovarian cancer development, progression, and 
recurrence. Historically, much of the research in this area has focused on reduction of 
primary cancer risk, failing to specifically study recurrence rates after clinical remission 
has been achieved. While there is a need for further research in this particular cohort, a 
CME course to provide health care providers with the most recent data on the topic is the 
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first step in creating awareness of this potentially life-altering intervention for ovarian 
cancer patients.  
Clinical and/or public health significance 
As the leading cause of gynecologic death, with survival rates that have remained largely 
unchanged despite chemotherapy and surgical interventions, ovarian cancer is in need of 
an intervention to prolong survival. A CME course outlining the most promising 
nutritional elements and their effect on cancer development, emphasizing the potential to 
decrease recurrence rates and prolong survival, would be beneficial in creating awareness 
in this area of research.  
The CME will equip PAs and other health care providers with the knowledge of 
the most recent advances in the area of nutrition and ovarian cancer. It will serve to 
spread awareness to the medical community as well as allow them to provide patients 
with the most up to date information. Attendees of the CME course will be able to 
provide their patients with nutritional and lifestyle recommendations to minimize 
development and recurrence of EOC.  
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